Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN

被引：0
作者：
Tina M. Schnöder
Judith Eberhardt
Michael Koehler
Holger B. Bierhoff
Sönke Weinert
Akhilesh Datt Pandey
Subbaiah Chary Nimmagadda
Denise Wolleschak
Korinna Jöhrens
Thomas Fischer
Florian H. Heidel
机构：
[1] Universitätsklinikum Jena,Innere Medizin II, Hämatologie und Onkologie
[2] Leibniz Institute on Aging,Department of Hematology and Oncology
[3] Fritz-Lipmann-Institute,Department of Genetics
[4] Otto-von-Guericke University Medical Center,Department of Cardiology
[5] Friedrich-Schiller-University,Institut für Pathologie
[6] Otto-von-Guericke University Medical Center,Collaborative Research Cluster 854 (CRC854), Medical Faculty
[7] Charité-Universitätsmedizin Berlin,undefined
[8] University Hospital Magdeburg,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2017年 / 143卷
关键词：
CXCL10; IP10; MPN; PV; ET; MF; Inflammation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：807 / 820
页数：13
相关论文
共 50 条
  • [41] Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCRRDB)
    Masykura, Najmiatul
    Habibah, Ummu
    Selasih, Siti Fatimah
    Gani, Soegiarto
    Irawan, Cosphiadi
    Somoastro, Sugiyono
    Utomo, Ahmad Rusdan Handoyo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04) : 220 - 227
  • [42] Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation
    Karla Bennemann
    Oliver Galm
    Stefan Wilop
    Claudia Schubert
    Tim H Brümmendorf
    Edgar Jost
    Clinical Epigenetics, 2012, 4
  • [43] The Clinical Significance of JAK2V617F Mutational Status on Phenotypic Features in Philadelphia-Negative Chronic Myeloproliferative Neoplasms
    Sahin, Ezgi
    Yonal-Hindilerden, Ipek
    Hindilerden, Fehmi
    Daglar-Aday, Aynur
    Nalcaci, Meliha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S337 - S338
  • [44] JAK2V617F mutation drives vascular resident macrophages toward a pathogenic phenotype and promotes dissecting aortic aneurysm
    Al-Rifai, Rida
    Vandestienne, Marie
    Lavillegrand, Jean-Remi
    Mirault, Tristan
    Cornebise, Julie
    Poisson, Johanne
    Laurans, Ludivine
    Esposito, Bruno
    James, Chloe
    Mansier, Olivier
    Hirsch, Pierre
    Favale, Fabrizia
    Braik, Rayan
    Knosp, Camille
    Vilar, Jose
    Rizzo, Giuseppe
    Zernecke, Alma
    Saliba, Antoine-Emmanuel
    Tedgui, Alain
    Lacroix, Maxime
    Arrive, Lionel
    Mallat, Ziad
    Taleb, Soraya
    Diedisheim, Marc
    Cochain, Clement
    Rautou, Pierre-Emmanuel
    Ait-Oufella, Hafid
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [45] Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm
    Rahman, Mohammed Ferdous-Ur
    Yang, Yue
    Le, Bao T.
    Dutta, Avik
    Posyniak, Julia
    Faughnan, Patrick
    Sayem, Mohammad A.
    Aguilera, Nadine S.
    Mohi, Golam
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [46] The Clinical Significance of JAK2V617F Mutation for Philadelphia-Negative Chronic Myeloproliferative Neoplasms in Patients with Splanchic Vein Thrombosis
    Hindilerden, Fehmi
    Hindilerden, Ipek Yonal
    Pinarbasi, Binnur
    Hancer, Veysel Sabri
    Kaymakoglu, Sabahattin
    Kucukkaya, Reyhan Diz
    Nalcaci, Meliha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S357 - S357
  • [47] SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F
    Koren-Michowitz, Maya
    Gery, Sigal
    Tabayashi, Takayuki
    Lin, Dechen
    Alvarez, Rocio
    Nagler, Arnon
    Koeffler, H. Phillip
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (06) : 811 - 820
  • [48] JAK2 inhibition in JAK2V617F-bearing leukemia cells enriches CD34+ leukemic stem cells that are abolished by the telomerase inhibitor GRN163L
    Dahlstrom, Jenny
    Xia, Chuanyou
    Xing, Xiangling
    Yuan, Xiaotian
    Bjorkholm, Magnus
    Xu, Dawei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 527 (02) : 425 - 431
  • [49] Targeting Endothelial-to-Mesenchymal Transition in a 3D iPSC-Based Model of JAK2V617F+Myeloproliferative Neoplasms
    Caduc, Madeline J.
    Lopez, Cristina Baquero
    Grasshoff, Martin
    Buhl, Eva Miriam
    Mabrouk, Mohamed H. Elsafi
    Ernst, Sabrina
    Wong, Dickson W. L.
    Mueller-Newen, Gerhard
    Vogt, Michael
    Eschweiler, Joerg
    Boor, Peter
    Ackermann, Maximilian
    Franzen, Julia
    Costa, Ivan G.
    Zenke, Martin
    Brummendorf, Tim H.
    Koschmieder, Steffen
    de Toledo, Marcelo Szymanski
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S421 - S422
  • [50] Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms
    Bermes, Max
    Rodriguez, Maria Jimena
    de Toledo, Marcelo Augusto Szymanski
    Ernst, Sabrina
    Mueller-Newen, Gerhard
    Bruemmendorf, Tim Henrik
    Chatain, Nicolas
    Koschmieder, Steffen
    Baumeister, Julian
    Levantini, Elena
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (24)
12345